NCT01726400View on ClinicalTrials.gov

In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia

CompletedOBSERVATIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

July 31, 2014

Conditions
Hepatitis C
Interventions
DRUG

Pegylated interferon alpha

Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.

DRUG

Ribavirin

Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.

Trial Locations (1)

6160

Fremantle Hospital, Fremantle

All Listed Sponsors
lead

Fremantle Hospital and Health Service

OTHER

NCT01726400 - In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia | Biotech Hunter | Biotech Hunter